BioCatalyst

Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone — catalyst calendar

1 verified catalyst event(s) referencing Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone, each linked to its official source. Verified as of 2026-08-06.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 4mo
ESTIMATED
 READOUT
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given D
Phase 2 · Refractory Metastatic Colorectal Cancer
 DCTH DELCATH SYSTEMS, INC. Melphalan/HDS Followed by Consolidation ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.